Corapril

Quick links to important sections

Corapril

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corapril

Property Description
Active Ingredients Ramipril, Hydrochlorothiazide (HCTZ)
Form Oral Tablet
Pharmacological Class Antihypertensive Agent; ACE Inhibitor/Thiazide Diuretic Combination
Common Purpose Maintenance of lowered blood pressure in adults
Origin Synthetic

What Type of Medicine is Corapril?

Corapril is a fixed-dose combination (FDC) antihypertensive agent that is available only by prescription. It belongs to the high-level pharmacological class of combination cardiovascular agents designed to manage elevated systemic arterial pressure (hypertension) in adults. This medicine is classified as a systemic agent because it exerts its effects throughout the entire body to lower blood pressure. It is administered via the oral route as a solid tablet, and its active compounds are synthetically derived. The use of FDCs like Corapril is often clinically recognized for promoting patient adherence compared to taking two separate monotherapies.


Corapril's Dual Composition: Ramipril and Hydrochlorothiazide

Corapril is composed of two distinct active ingredients (INN): Ramipril and Hydrochlorothiazide (HCTZ). This combination strategy is known as combination therapy, which includes the two ingredients in a single pill, alongside solid pharmaceutical excipients necessary to form the tablet structure. Ramipril is categorized as an Angiotensin-Converting Enzyme (ACE) inhibitor, while Hydrochlorothiazide is a thiazide diuretic. This pairing is a standard therapeutic approach where the medicine works by simultaneously targeting fluid balance and vascular tone. Other commonly available FDC formulations containing this exact composition include Tritace HCT and various generic Ramipril/HCTZ tablets.


General Purpose of this Combination Therapy

The general purpose of Corapril is to help maintain blood pressure within a healthier range by employing complementary actions against hypertension. This is typically used as a maintenance therapy for individuals whose blood pressure is not adequately controlled by either Ramipril or a diuretic alone. The medicine achieves this through a synergistic effect: the Ramipril component supports the relaxation of blood vessels (vasodilation) by inhibiting the renin-angiotensin-aldosterone system (RAAS), and the HCTZ component promotes volume reduction by helping the kidneys excrete excess sodium and water. This dual mechanism reduces the persistent force exerted on the arterial walls, contributing to long-term cardiovascular health.

Regulatory References

  1. PubChem
  2. MedlinePlus

What side effects are possible with Corapril?

Possible side effects and safety information

Corapril's official safety profile, based on regulatory documentation, details possible adverse reactions categorized by frequency and the body system affected. Adverse reactions are classified using standard governmental frequency bands.

Common effects (occurring in 1% to 10% of users) generally include headache, dizziness, a non-productive, tickling cough, fatigue, and symptomatic hypotension (low blood pressure). Gastrointestinal disturbances such as vomiting, nausea, and diarrhea are also listed as common. Metabolic changes often involve increases in blood potassium levels (hyperkalemia).

Serious Adverse Reactions highlighted in official labeling require immediate attention. These include angioedema (swelling of the face, tongue, or throat, which can be life-threatening) and rare but severe events like acute renal failure and hepatic failure. Furthermore, long-term, cumulative use of the hydrochlorothiazide component is associated with an increased risk of Non-melanoma skin cancer (Basal Cell and Squamous Cell Carcinoma).

Population-Specific Safety Constraints exist. Corapril is contraindicated in the second and third trimesters of pregnancy due to a documented risk of fetal injury and death. It is also contraindicated in patients with severe renal impairment, a history of ACE inhibitor-related angioedema, or specific electrolyte imbalances.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Corapril is officially documented to cause severe manifestations primarily related to profound systemic hypotension and severe fluid and electrolyte imbalance.

Documented presentations include excessive vasodilation leading to marked low blood pressure, syncope (fainting), and alterations in heart rhythm such as tachycardia. Signs of electrolyte imbalance, such as dehydration, confusion, and potential seizures, are also noted. Overexposure may accelerate acute renal failure or progressive azotemia, particularly in patients with pre-existing renal impairment.

Life-Threatening Outcomes and Required Action: Immediate medical attention is mandated for life-threatening outcomes, including the potential for fatal angioedema (swelling of the face, tongue, or throat) and Acute Respiratory Distress Syndrome (ARDS). An excessive fall in blood pressure may also precipitate a myocardial infarction or stroke in high-risk patients.

In the event of suspected overdose, regulators advise contacting emergency services, a regional poison control center, or the nearest hospital emergency department immediately, especially if passing out or trouble breathing occurs. Management is described as symptomatic and supportive. No specific antidote is known; however, interventions like the administration of intravenous sodium chloride for hypotension and epinephrine for life-threatening angioedema are documented supportive measures.

Therapeutic Uses of Corapril

What Corapril Treats: Main Uses and Benefits

Corapril is a prescription medication utilized in therapeutic domains to manage certain cardiovascular conditions. The primary use of Corapril is to address essential hypertension (high blood pressure) in adult patients. High blood pressure is a condition that, if unaddressed, may contribute to significant health concerns over time.

Its intended benefit is to help regulate blood pressure levels. For patients whose blood pressure is not managed effectively by single-drug therapy (monotherapy), Corapril provides an additional option to support established blood pressure goals. By facilitating the management of high blood pressure, Corapril may assist in reducing the overall strain on the cardiovascular system.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Corapril

The fixed-dose combination Corapril (Ramipril/Hydrochlorothiazide) is officially approved for use in adults (18 years and older) who require treatment for essential hypertension. Regulatory authorities have defined strict non-eligibility rules, classifying certain groups as contraindicated (absolutely prohibited) or not recommended.


Contraindicated Populations

Corapril is contraindicated for patients with a history of Angioedema (severe swelling related to a previous ACE inhibitor) or known Hypersensitivity to Ramipril, Hydrochlorothiazide, or any sulfonamide-derived drugs. Use is also strictly prohibited in patients with severely impaired renal function (creatinine clearance less than 30 mL/min), severe hepatic impairment, or Anuria. The medicine must not be used by patients with Diabetes Mellitus who are taking the drug Aliskiren, or those taking Sacubitril/Valsartan.

Age- and Condition-Based Restrictions

Corapril is Contraindicated during the second and third trimesters of pregnancy and its use is not recommended during the first trimester or while breastfeeding. The medicine is not recommended for the pediatric population (under 18 years) because safety and efficacy have not been established in this age group. Older adults may require greater caution and careful monitoring due to the potential for existing renal or hepatic impairment.

What should I know about interactions with other medicines?

Corapril's official interaction profile is defined by its dual composition, leading to documented pharmacokinetic and pharmacodynamic constraints. Certain combinations are formally contraindicated. Co-administration with the Neprilysin Inhibitor Sacubitril/Valsartan is strictly prohibited, requiring an official 36-hour cessation period when switching to or from Corapril. Dual blockade of the Renin-Angiotensin System with Aliskiren or Angiotensin II Receptor Blockers (ARBs) is contraindicated in patients with Diabetes Mellitus or defined Renal Impairment (GFR < 60 mL/min/1.73 m^2).

The profile documents multiple pharmacodynamic reinforcements. Co-administration with Potassium-elevating agents (including certain supplements and diuretics) significantly increases the documented risk of Hyperkalemia. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a loss of antihypertensive effect and increase the risk of renal function deterioration. Furthermore, mTOR Inhibitors (e.g., Everolimus) and Gliptins are documented to increase the risk of Angioedema.

Regarding substance clearance, the Hydrochlorothiazide component reduces the renal clearance of Lithium, significantly raising the risk of Lithium toxicity. An administration timing rule applies to Bile Acid-Binding Resins (e.g., Cholestyramine), which must be taken at least 4 hours before or 4 to 6 hours after Corapril to prevent a documented reduction in diuretic absorption. Alcohol may potentiate orthostatic hypotension.

Mechanism of Action

Corapril functions as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE). Its primary molecular target is the zinc ion within the active site of ACE, which is found predominantly on the surface of vascular endothelial and renal cells.

This inhibition blocks the enzymatic cleavage of the decapeptide angiotensin I to the active octapeptide angiotensin II. The resulting decrease in circulating angiotensin II reduces the stimulation of the angiotensin II type 1 ( AT1) receptors on vascular smooth muscle.

The intracellular pathway consequence is a reduction in AT1-mediated signaling, which normally triggers vasoconstriction via activation of the inositol trisphosphate/diacylglycerol signaling cascade. Downstream, decreased angiotensin II levels reduce the adrenal cortical secretion of aldosterone, a mineralocorticoid. The system-level physiological consequence of this mechanism is generalized vasodilation, reduced peripheral vascular resistance, and enhanced renal excretion of sodium and water due to lower aldosterone-mediated reabsorption. Corapril also impedes the breakdown of the vasodilator peptide bradykinin by ACE.

Dosage and Administration Information

How Corapril Is Used: Administration Guidelines

Corapril (Ramipril/Hydrochlorothiazide) is a prescription medicine used according to established administration protocols. The instructions below detail the administration rules, focusing solely on the how and when of its use, and do not contain information on therapeutic benefits or safety.


Dosing and Administration Protocol

Administration Scope Administration Details
Route of Administration Oral route (swallowed).
Dosing Frequency The tablet must be taken once daily.
Timing and Intake Can be taken before, with, or after meals. It should be taken at the same time each day, preferably in the morning.
Preparation Requirements The tablet must be swallowed whole with liquid; it must not be chewed or crushed.
Standard Dosing Principle Use of the fixed-dose combination generally follows prior dose stabilization on the individual components. Doses may be gradually increased at intervals of at least 2 to 3 weeks, up to a maximum daily dose of Ramipril 10 mg / HCTZ 25 mg.

Population-Specific Administration Rules

Specific limitations on administration apply to certain patient groups:

  • Pediatric Population: Use is not recommended in children and adolescents under 18 years of age due to insufficient data.
  • Older Adults: Treatment should be initiated with lower doses, and any subsequent dose adjustments must be made more gradually.
  • Impaired Kidney/Liver Function: Specific dose maximums apply. For example, the maximum daily dose is Ramipril 5 mg / HCTZ 25 mg for patients with moderate kidney impairment (CrCl 30 to 60 mL/min). The medicine is contraindicated in severe impairment.

Before initiating Corapril, administration protocols involve considering the reduction or temporary discontinuation of any pre-existing diuretic to mitigate initial effects, or starting with the lowest Ramipril monotherapy dose first.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Corapril

Information about Corapril (Ramipril and Hydrochlorothiazide combination) is based on regulatory-reviewed research. This research includes controlled trials and large-scale studies focused on the evaluation of its active ingredients in high blood pressure and related health outcomes. The findings describe group patterns observed in the studies and help contextualize how patients reported their experience.


Research Examining Essential Hypertension

Research has examined the use of the Ramipril/Hydrochlorothiazide combination in adults with high blood pressure. The core evidence stems from Randomized Controlled Trials (RCTs) and systematic reviews. Researchers designed these studies to measure outcomes related to systemic or functional balance, specifically looking at changes in blood pressure readings (Systolic Blood Pressure or SBP, and Diastolic Blood Pressure or DBP).

Studies reported how blood pressure evolved in the observed populations. Findings reported patterns where participants achieved pre-defined blood pressure targets when receiving the combination compared to those receiving monotherapy or placebo. The data show patterns related to how blood pressure levels evolved in the observed populations.


Research Exploring Cardiovascular Risk and Long-Term Outcomes

Research has also examined the relationship between the use of this drug class combination for high blood pressure and the potential for long-term outcomes. Studies explored whether long-term use for high blood pressure was associated with fewer major health events over time. This evidence is derived not just from short-term trials but also from extensive meta-analyses that pool data from many studies on ACE inhibitors and diuretics, alongside large observational studies.

Research monitored outcomes such as the incidence of stroke, heart attack, and hospitalization due to heart failure. Research monitored the incidence of these serious cardiovascular outcomes when these drug types were used, but this evidence primarily reflects the drug classes generally.


Key Limitations and What Remains Uncertain in Research

The evidence base for Corapril contains several research gaps. There is limited information for long-term outcomes specifically designed for the Corapril fixed-dose combination (FDC). The long-term effects are not fully established for the FDC compared to other therapeutic options. Another research limitation is that follow-up durations were limited in the initial research trials, meaning there is less direct insight into the durability of blood pressure control beyond the first year. Research is ongoing to further examine these patterns and contribute to the existing evidence.

Frequently Asked Questions (FAQ)

Common questions about Corapril (FAQ)


Q: Why do doctors prescribe Corapril instead of other similar drugs?

A: Official documents describe that Corapril is a fixed-dose combination, meaning it contains two active substances that have complementary effects in lowering blood pressure. The combined effect is reported to be greater than using either ingredient alone. Using a combination product is also often recognized as an approach to simplify treatment by reducing the number of tablets a patient needs to take.


Q: Is it normal to feel tired when first starting Corapril?

A: Fatigue and dizziness are listed as common adverse reactions in the official safety profiles for Corapril. These effects are often associated with the initial adjustment to changes in blood pressure. Concerns about persistent or concerning fatigue can be reviewed with a prescribing healthcare professional.


Q: Can Corapril be taken at the same time as my daily vitamin?

A: Official drug interaction profiles generally lack specific warnings regarding standard multivitamins. However, warnings are documented for supplements that contain potassium, as taking them with Corapril can increase the risk of high potassium levels (hyperkalemia). Information regarding all supplements, including vitamins, is typically reviewed by a healthcare professional.


Q: What happens if I miss a dose of Corapril?

A: If a dose is missed, regulatory instructions suggest taking it as soon as possible, unless it is almost time for the next scheduled dose. Official guidance indicates that doses should not be doubled to make up for a missed dose. If there is uncertainty about the timing, official information suggests reviewing the missed dose situation with a healthcare provider.


Q: What is the risk of Corapril interacting with over-the-counter pain relievers?

A: Official labeling documents warn about co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common over-the-counter pain relievers. This interaction is documented to potentially reduce the blood-pressure-lowering effect of Corapril. It may also increase the risk of problems related to kidney function.


Q: Does Corapril affect a person's ability to drive or operate machinery?

A: Official patient information states that this medicine can cause side effects like light-headedness, dizziness, and fainting, particularly after the first few doses or after a dose increase. Official guidance suggests caution regarding driving or operating machinery until an individual is aware of how they respond to the medication.


Q: Do official medical warnings exist for taking Corapril with alcohol?

A: Yes, official labeling contains a warning about the combination of Corapril and alcohol. Alcohol may potentiate, or increase, the likelihood of a significant drop in blood pressure when standing up (orthostatic hypotension). This effect is related to the drug's properties.


Q: What are the main things Corapril works on in the body?

A: Corapril works through its two main components. The Ramipril part helps relax blood vessels by blocking an enzyme in a hormone system. The Hydrochlorothiazide part, which is a diuretic, helps the kidneys remove excess sodium and water from the body. These two actions work together to lower blood pressure.


Q: Is it possible to be allergic to Corapril?

A: Yes, Corapril is contraindicated in patients with a history of hypersensitivity (allergic reaction) to Ramipril, Hydrochlorothiazide, or any sulfonamide-derived drugs. Serious allergic reactions, such as severe swelling of the face or throat known as angioedema, are explicitly documented in official safety information.


Q: Is Corapril known to interact with herbal supplements?

A: Official sources generally focus interaction warnings on prescription drugs, over-the-counter medicines, and certain substances like alcohol. Specific data for most herbal remedies and supplements is often limited. Regulatory bodies typically recommend that individuals report all use of supplements to a healthcare professional.


Q: What is the expected long-term safety profile of Corapril?

A: Official warnings exist regarding the long-term use of the Hydrochlorothiazide component. Long-term, cumulative use is associated with an increased risk of Non-melanoma skin cancer (Basal Cell and Squamous Cell Carcinoma). Regulatory documents describe the importance of checking for and reporting any new or changing skin lesions.


Q: Are there any warnings for people with diabetes taking Corapril?

A: Official warnings include a strict contraindication (prohibition) for patients with diabetes who are also taking the drug Aliskiren. Additionally, the diuretic component may affect how the body handles glucose (sugar), which could potentially lead to a deterioration of existing metabolic control in patients with diabetes mellitus.


Q: How quickly should I expect to feel a change after starting Corapril?

A: Regulatory data indicates that the effect on blood pressure typically begins to be apparent within 1 to 2 hours of administration. The peak effect is usually reached within 3 to 6 hours after the dose. However, the optimal, stable therapeutic effect generally requires regular administration for approximately 2 to 4 weeks.


Q: Does Corapril have a long-term effect on my condition?

A: Clinical studies described in regulatory summaries examine the use of this drug class in maintaining long-term blood pressure control. Researchers designed these studies to explore whether long-term use for high blood pressure was associated with fewer major cardiovascular events, such as stroke or heart attack, over time.


Q: What kind of monitoring is needed while I am taking Corapril?

A: Regulatory information indicates that patients should be monitored closely for evidence of changes in fluid or electrolyte balance, such as low potassium levels. Monitoring of kidney function and serum potassium levels, typically through blood tests, is often required.


Q: Why do some people take Corapril in the morning and others at night?

A: Official guidelines state the tablet must be taken once daily and is preferably taken in the morning. This timing is preferred because the drug's effect lasts about 24 hours, but the diuretic component might increase urination. In some circumstances, the dose timing may be adjusted by a professional if the blood pressure-lowering effect is not sustained throughout the full 24-hour period.


Q: What should I do if a potential side effect doesn't go away?

A: Official safety documents contain general guidance stating that if adverse reactions are moderate or severe, the medication dosage may be reduced or therapy may be withdrawn. Decisions regarding dosage adjustment or discontinuation are generally managed in consultation with a prescribing healthcare professional.


Q: Can Corapril cause problems with sleeping (insomnia)?

A: While insomnia is not consistently listed as a common side effect in official documents, other nervous system and psychiatric disturbances are listed. These include possible effects such as restlessness and vertigo, which could potentially impact sleep quality in some individuals.


Q: How long does Corapril stay in my system?

A: Regulatory pharmacokinetic data for the active metabolite, ramiprilat, indicates that the effective half-life of its concentration is typically between 13 to 17 hours for higher doses. This half-life measurement is one factor that determines how often the drug should be administered to maintain a consistent effect.


Q: Can Corapril affect the results of a blood test?

A: Yes, regulatory documents note that the medicine can lead to changes in electrolyte and metabolic balance, which are measured by blood tests. Specifically, there are monitoring requirements for serum potassium, and the Hydrochlorothiazide component may affect calcium and uric acid levels.


Q: Does Corapril help with cholesterol levels?

A: Corapril is not indicated for the purpose of treating or helping with cholesterol levels. Official warnings for the Hydrochlorothiazide component list a potential increase in serum cholesterol and triglycerides as a possible metabolic effect that may occur in some individuals.


Q: What happens if I accidentally take two doses of Corapril?

A: The overdosage section of official labeling describes the primary documented effect as an excessive lowering of blood pressure (hypotension). Official guidance indicates that patients should not take more than the prescribed amount. Accidental double doses are typically reviewed with a healthcare professional.


Q: Can Corapril cause changes in mood or behavior?

A: Official safety documents list nervous system and psychiatric disturbances as possible adverse effects. These include possible changes such as restlessness and, rarely, reports of confusion associated with the medication.


Q: Why is it important not to share Corapril with others?

A: Corapril is a prescription-only medicine because the dose is highly individualized. Official labeling indicates that the dose is carefully determined based on the patient’s specific blood pressure response and pre-existing medical conditions, such as kidney function. It is intended only for the person for whom it was prescribed.


Q: What is the official classification of Corapril?

A: Corapril is classified as an Antihypertensive Agent belonging to the pharmacological class of Angiotensin-Converting Enzyme (ACE) Inhibitor/Thiazide Diuretic Combinations. It is regulated as a prescription-only medicine (POM).

How should Corapril be stored and disposed of?

How to Store and Dispose of Corapril?

The storage and disposal of Corapril (Ramipril/Hydrochlorothiazide) tablets must adhere to official regulatory conditions to ensure stability and public safety.

Official Storage Requirements

Corapril must be stored at Controlled Room Temperature, specifically between 20^circ to 25 C (68^circ to 77 F). The medicine must be kept in a tight, light-resistant container and protected from both excessive light and moisture. Freezing the product is strictly prohibited. As a mandatory safety measure, the medicine must be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired tablets should be disposed of using an authorized drug take-back program whenever possible. If a take-back program is unavailable, the official household disposal method requires mixing the medicine with an undesirable substance (such as used coffee grounds) and placing the mixture in a sealed container before discarding in the household trash. Tablets must not be flushed down the toilet or poured down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Corapril found in:

A-Z Index: